270 related articles for article (PubMed ID: 16048747)
1. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
Arin MJ; Hunzelmann N
Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
Allen KJ; Wolverton SE
J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in severe pemphigus.
Schmidt E; Goebeler M; Zillikens D
Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
[TBL] [Abstract][Full Text] [Related]
5. A review of rituximab in cutaneous medicine.
Scheinfeld N
Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
7. Delayed response of oral pemphigus vulgaris to rituximab treatment.
Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
[TBL] [Abstract][Full Text] [Related]
8. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
12. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
Prodanovic EM; Korman NJ
J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
14. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
Mease PJ
J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
[TBL] [Abstract][Full Text] [Related]
15. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.
Schadlow MB; Anhalt GJ; Sinha AA
J Drugs Dermatol; 2003 Oct; 2(5):564-7. PubMed ID: 14558407
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
20. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment.
Connelly EA; Aber C; Kleiner G; Nousari C; Charles C; Schachner LA
Pediatr Dermatol; 2007; 24(2):172-6. PubMed ID: 17461818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
